Biocytogen will be exhibiting and hosting 1-on-1 meetings at BIO-EUROPE 2023, taking place from November 6-8, 2023 in Munich, Germany. Biocytogen is thrilled to be part of this premier event, showcasing our latest innovations in clinical and preclinical therapeutic asset discovery and development. Here’s how to connect with us at the event:
- Booth #60: Connect with our Business Development & Licensing team at the booth to gain insights into the most recent developments in our diverse therapeutic portfolio.
- Schedule 1-on-1 Meetings: Private meetings with our experts will allow you to delve deeper into our portfolio, to find solutions suitable for your therapeutic programs.
Don’t miss this opportunity to learn more about our seven state-of-the-art, fully human antibody and T-cell receptor (TCR) discovery platforms, designed to unlock new possibilities in drug development for a variety of modalities. These cutting-edge platforms are made possible by our fully human antibody/TCR RenMice® series, including RenMab®, RenLite®, RenNano®, RenTCRTM and RenTCR-mimicTM mice. RenMice have been well-recognized in the biotech and biopharmaceutical industry, with 42 target-nominated discovery projects having been established by worldwide partners.
Biocytogen’s Project Integrum, a RenMice KO-based fully human antibody-based drug discovery initiative for 1000+ targets, has also recently met important milestones:
- Completion of 900 target antibody discovery projects
- Generation of a library containing 400k – 500k fully human antibody sequences
- Identification of 30+ PCC-stage molecules.
As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements have been established worldwide. The company’s pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. With the establishment of Project Integrum’s antibody library, Biocytogen will extend its partnerships on the off-the-shelf antibody sequences and work with collaborators to expedite the development of selected antibodies entering the clinic.
We look forward to discussing licensing and co-development opportunities with you, either for antibody assets or fully human drug discovery platforms.
